Uploaded July 2019 | Updated November 2026, 3 hours ago
I’m Christine Simmon, Senior Vice President of Policy and Executive Director of the Biosimilars Council at the Association for Accessible Medicines.
Working in this sector, I know how it feels to be inundated with invites to conferences and seminars and workshops and webinars -- all of which are supposed to help you stay on top of biosimilars. It’s a lot!
I can make this much simpler – because there is no conference you can attend that brings together the caliber of speakers and resources – and provides as deep a dive into the early successes and ongoing challenges of the biosimilars market in the U.S. – other than GRx+Biosims, November 4-6, in Bethesda, Maryland.
You really will want to be part of the conversation and take advantage of our biosimilars programming.
The conference will include sessions on:
• The federal focus on biosimilars;
• Regulatory issues for biosimilars;
• Overcoming anti-competitive tactics that block biosimilar adoption; and
• A discussion with industry leaders on commercializing biosimilars.
We look forward to you joining your peers at GRx+Biosims, November 4-6. #GRxBiosims
Learn more at grxbiosims.org
I’m Christine Simmon, Senior Vice President of Policy and Executive Director of the Biosimilars Council at the Association for Accessible Medicines.
Working in this sector, I know how it feels to be inundated with invites to conferences and seminars and workshops and webinars -- all of which are supposed to help you stay on top of biosimilars. It’s a lot!
I can make this much simpler – because there is no conference you can attend that brings together the caliber of speakers and resources – and provides as deep a dive into the early successes and ongoing challenges of the biosimilars market in the U.S. – other than GRx+Biosims, November 4-6, in Bethesda, Maryland.
You really will want to be part of the conversation and take advantage of our biosimilars programming.
The conference will include sessions on:
• The federal focus on biosimilars;
• Regulatory issues for biosimilars;
• Overcoming anti-competitive tactics that block biosimilar adoption; and
• A discussion with industry leaders on commercializing biosimilars.
We look forward to you joining your peers at GRx+Biosims, November 4-6. #GRxBiosims
Learn more at grxbiosims.org










